Defibrotide reduces procoagulant activity and increases fibrinolytic properties of endothelial cells
Author:
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Cancer Research,Hematology
Link
http://www.nature.com/articles/2403004.pdf
Reference45 articles.
1. Bianchi G, Barone D, Panzarotti E, Tettamanti R, Porta R, Moltrasio D et al. Defibrotide, a single-stranded polydeoxyribonucleotide acting as an adenosine receptor agonist. Eur J Pharmacol 1993; 238: 327–334.
2. Cimminiello C . Clinical trials with defibrotide in vascular disorders. Semin Thromb Hemost 1996; 22 (Suppl. 1): 29–34.
3. Violi F, Marubini E, Coccheri S, Nenci GG . Improvement of walking distance by defibrotide in patients with intermittent claudication. Results of randomized, placebo-controlled study. Thromb Haemost 2000; 83: 672–677.
4. Palmer KJ, Goa KL . Defibrotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in vascular disorders. Drugs 1993; 45: 259–294.
5. Bearman SI . The syndrome of hepatic veno-occlusive disease after bone marrow transplantation. Blood 1995; 85: 3005–3020.
Cited by 107 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. sVEGF-R1 in acute non-infectious toxicity syndromes after pediatric allogeneic hematopoietic stem cell transplantation;Transplant Immunology;2024-02
2. Defibrotide modulates pulmonary endothelial cell activation and protects against lung inflammation in pre-clinical models of LPS-induced lung injury and idiopathic pneumonia syndrome;Frontiers in Immunology;2023-06-27
3. Defibrotide mitigates endothelial cell injury induced by plasmas from patients with COVID-19 and related vasculopathies;Thrombosis Research;2023-05
4. Transplant-Associated Thrombotic Microangiopathy in the Context of Allogenic Hematopoietic Stem Cell Transplantation: Where We Stand;International Journal of Molecular Sciences;2023-01-06
5. Early vascular endothelial complications after hematopoietic cell transplantation: Role of the endotheliopathy in biomarkers and target therapies development;Frontiers in Immunology;2022-11-21
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3